The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising especially a fatty acid as a percutaneous absorption promoter, at least one alcoholic vehicle and also a stabilizer capable of stabilizing the fatty acid in the said pharmaceutical composition. A processor provides a first initial signal and switches to a first display mode when a select signal is asserted. The optical connector is connected to the optical transmission unit such that light from the semiconductor optical amplifier is incident on one of the plurality of diffraction gratings. Each bearing assembly is mounted to the underside of the seat slide top member, so that the bearing assemblies move along with the seat slide top member on an upper wall defined by a base.